<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45547">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513303</url>
  </required_header>
  <id_info>
    <org_study_id>VT-304</org_study_id>
    <nct_id>NCT02513303</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Sirolimus-Eluting Collagen Implant to Assess AV Fistula Outcomes in Patients on Hemodialysis</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant in Subjects on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of the Sirolimus-eluting Collagen
      Implant will improve AV Fistula outcomes, including time to first dialysis and suitability
      for dialysis at 6 months, in subjects undergoing surgical creation of an AV fistula for
      providing vascular access for hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first dialysis (TTFD)</measure>
    <time_frame>Assessments to determine the suitability for first cannulation of the AV fistula will start 28 days following surgery.</time_frame>
    <description>Time To First Dialysis (TTFD): defined as the time from fistula creation to the time when the fistula can support three consecutive dialysis sessions using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fistula Suitability for Dialysis at 6 Months (FSD6)</measure>
    <time_frame>Assessed during a 30-day suitability ascertainment period that begins 150 days after fistula creation</time_frame>
    <description>Fistula Suitability for Dialysis at 6 Months (FSD6): defined as the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">245</enrollment>
  <condition>Complication of Renal Dialysis</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>End Stage Kidney Disease</condition>
  <condition>ESRD</condition>
  <condition>Chronic Kidney Failure</condition>
  <condition>Complication of Hemodialysis</condition>
  <condition>Vascular Access Complication</condition>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV fistula surgery with investigational product (Sirolimus-eluting Collagen Implant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>AV fistula surgery without investigational product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Subjects in the treatment group will receive a single prophylactic dose of sirolimus delivered locally to the vessel wall at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery. Control group subjects will have surgery for creation of the AV fistula but will not receive the drug.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently on hemodialysis for ≤12 months

          -  Vascular anatomy suitable for creation of the AV fistula, determined by pre procedure
             duplex ultrasound

          -  Successful creation of a single stage radiocephalic or brachiocephalic end to side
             fistula

        Exclusion Criteria:

          -  Prior AV access created on the limb where the fistula surgery is planned

          -  ST-elevation MI or cerebrovascular accident within 30 days of the index procedure

          -  Known hypersensitivity to the following: sirolimus, beef or bovine collagen

          -  Hypotension with systolic blood pressures &lt;100 mm Hg at the time of screening

          -  Known or suspected active infection at the time of the AV fistula surgery

          -  Known to be HIV positive

          -  Prisoner, mentally incompetent, and/or alcohol or drug abuser
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Iyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vascular Therapies, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh Raghubanshi</last_name>
    <phone>201-266-8310</phone>
    <email>rakesh@vasculartx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Kornhauser, EdD</last_name>
    <phone>954-341-1440</phone>
    <email>david@vasculartx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nephrology Consultants, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Service</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Diego Institute of Medical Research</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 8, 2016</lastchanged_date>
  <firstreceived_date>July 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>End Stage Kidney Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Chronic Kidney Failure</keyword>
  <keyword>Chronic Renal Failure</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Access</keyword>
  <keyword>Arteriovenous Fistula</keyword>
  <keyword>AV Fistula</keyword>
  <keyword>AVF</keyword>
  <keyword>Nephrology</keyword>
  <keyword>Vascular Surgery</keyword>
  <keyword>Dialysis Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
